Skip to content
10-Q

Quarterly Report

Cascadian Therapeutics, Inc.

0001193125-17-164184

← back to feed
Filed
May 9, 2017 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2017 · May 9, 2017 49.24M sh
Capex Q1 2017 · Mar 31, 2017 $95K
Capex Q1 2017 · Mar 31, 2016 $59K
Short Term Investments Q1 2017 · Mar 31, 2017 $90.22M
Short Term Investments Q1 2017 · Dec 31, 2016 $49.08M
Cash And Equivalents Q1 2017 · Mar 31, 2017 $35.67M
Cash And Equivalents Q1 2017 · Dec 31, 2016 $13.72M
Cash And Equivalents Q1 2017 · Mar 31, 2016 $13.88M
Cash And Equivalents Q1 2017 · Dec 31, 2015 $27.85M
Stockholders Equity Q1 2017 · Mar 31, 2017 $151.69M
Stockholders Equity Q1 2017 · Dec 31, 2016 $74.36M
Current Liabilities Q1 2017 · Mar 31, 2017 $5.38M
Current Liabilities Q1 2017 · Dec 31, 2016 $8.77M
Current Assets Q1 2017 · Mar 31, 2017 $127.82M
Current Assets Q1 2017 · Dec 31, 2016 $64.45M
Total Assets Q1 2017 · Mar 31, 2017 $157.17M
Total Assets Q1 2017 · Dec 31, 2016 $83.27M
Sga Expense Q1 2017 · Mar 31, 2017 $2.98M
Sga Expense Q1 2017 · Mar 31, 2016 $6.63M
Rd Expense Q1 2017 · Mar 31, 2017 $8.59M
Rd Expense Q1 2017 · Mar 31, 2016 $6.34M
Net Income Q1 2017 · Mar 31, 2017 −$11.4M
Net Income Q1 2017 · Mar 31, 2016 −$12.89M
Operating Income Q1 2017 · Mar 31, 2017 −$11.56M
Operating Income Q1 2017 · Mar 31, 2016 −$12.97M